

The amendments to page 46 of the specification are made to identify the residues of myostatin represented by SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. These amendments are supported by page 46 of the specification and by Figure 1.

Conclusion

Applicant respectfully submits that the claims are in condition for allowance and notification to that effect is requested. The Examiner is invited to telephone Applicant's attorney (612-373-6959) to facilitate prosecution of this application.

If necessary, please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

Respectfully submitted,

MOHAMED E. EL HALAWANI ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6959

Date

October 11, 2001

By



Janet E. Emperson
Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 11 day of October, 2001.

Name

Seattamattie Greg

Signature

Seattamattie Greg

FOI b7D - 92845260

Clean Version of the First Full Paragraph of Page 46

USE OF PASSIVE MYOSTATIN IMMUNIZATION

Applicant: Mohamed E. El Halawani et al.

Serial No.: 09/754,826

AI
Myostatin peptides were prepared. The peptides were C1 (Asn-Met-Leu-Tyr-Phe-Asn-Gly-Lys-Glu-Gln-Ile-Ile-Tyr-Gly-Lys-Ile; residues 83-98; SEQ ID NO:4), D1 (Asp-Cys-Asp-Glu-His-Ser-Thr-Glu-Ser-Arg-Cys; residues 5-15; SEQ ID NO:5), and E1 (Ile-Ala-Pro-Lys-Arg-Tyr-Lys-Ala-Asn; residues 33-41; SEQ ID NO:6). Each received a peptide immunogen and the sequences were chosen based on relative hydrophilicity/hydrophobicity.

09/754,826 - 101601